EP382: Pharma Conflicts of Interest and the Anti-Kickback Statute, With Aaron Mitchell, MD, MPH

Pharma Conflicts of Interest and the Anti-Kickback Statute, With Aaron Mitchell, MD, MPH. Even a Free Lunch Can Skew a Doctor's Prescribing—What the Anti-Kickback Statute Does and Doesn't Catch. Episode 382. Stacey Richter talks with Aaron Mitchell, MD, MPH, a medical oncologist and health services researcher at Memorial Sloan Kettering Cancer Center, about conflicts of interest in pharma payments to physicians and where the current anti-kickback statute falls short. WHAT YOU'LL LEARN ✅ Why data shows that even modest payments—including free lunches—measurably skew physician prescribing ✅ The difference between clearly impermissible conflicts of interest and the harder-to-judge gray areas of pharma-physician payments ✅ How to weigh the aggregate good of legitimate clinical-expert collaboration against the aggregate harm of overprescribing ✅ Why patient populations can end up overmedicated or overdiagnosed as a result of industry payments to physicians ✅ What role payers could play in identifying and correcting skewed prescribing patterns ✅ What solutions—from stricter bans to physician self-regulation—could curb harmful conflicts of interest without stifling legitimate innovation WHY THIS MATTERS The debate over pharma payments to physicians usually gets flattened into corruption versus necessary collaboration. Mitchell's research shows the truth is more nuanced—and understanding where real harm happens, and where it doesn't, is essential for any stakeholder trying to design smarter guardrails than a blanket ban or an anything-goes status quo. MENTIONED IN THIS EPISODE No past-episode citations in this episode's timestamped chapter list. === LINKS === 🔗 Show Notes with all mentioned links: Episode Page ✉️ Enjoy this podcast? Subscribe to the free weekly newsletter 🫙 Support the podcast with a small donation to the Tip Jar 📺 Subscribe to our YouTube channel 🎤 Listen on Apple Podcasts 🎤 Listen on Spotify === CONNECT WITH THE RHV TEAM === ✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X 00:00 Introduction. 07:32 How does the recent whistleblower case serve as a good example of what shouldn't be permissible in Pharma? 11:23 "There's a little bit of a disconnect between what the law currently says and maybe the ideal world that we would want." 14:37 How should stakeholders react to this new legislation? 17:56 What is the aggregate benefit versus risk of these payments to doctors? 23:51 What should providers and the federal government be doing in light of this new legislation? 29:07 "It's just always so much harder to get to the outcomes because there's so much more that happens in between the clinical decision and then what the patient's outcome is down the road." 30:42 Will innovation be stifled with this new crackdown on kickbacks?